Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Sep
10
Today In Oncology
FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma
NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo